gilead sciences inc
Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations
Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19
Dr Reddy's inks licensing pact with Gilead Sciences for Remdesivir
Gilead Sciences signed similar non-exclusive licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila
Despite FDA warning, Trump says he is taking hydroxychloroquine
The Food and Drug Administration has issued a warning about its use
1 of 1